The FTSE 100 ended a difficult week firmly in negative territory on Friday, dragged lower by surging oil prices and growing unease over artificial intelligence investment returns. The blue-chip index closed down
Ipsen has announced that its Bylvay drug has failed to meet the primary endpoint in a major Phase 3 clinical trial targeting biliary atresia in young children. The French pharmaceutical company revealed
More
A New York state court has denied a motion to dismiss a fraud lawsuit filed by Attorney General Letitia James against the operator of a peer-to-peer payment network. The ruling, issued on
More
A social media video began circulating showing a couple engaged in a midday makeout session on a public park bench in plain sight. The original poster shamed the pair with the classic
More
RTX Corporation delivered stronger-than-expected results for the second quarter of 2026, sending its stock sharply higher as investors welcomed the upbeat performance. The defence and aerospace giant has continued to benefit from
More
Andy Burnham’s pledge to cut business rates for pubs, clubs and music venues is expected to save each venue more than £1,000 next year, in a move carrying a £100m price tag.
More
A coalition of 11 states and the District of Columbia filed an amicus brief on July 13 supporting Colorado in a high-stakes federal appeals court case over interest-rate limits. Two former FDIC
More
Small and solo law firms are discovering that accepting a simple prepaid consultation fee through a self-scheduled platform is far more complicated than it should be. The promise of self-scheduled, prepaid consultations
More
IMAX Corporation delivered an impressive set of second-quarter 2026 financial results, sending shares climbing sharply as investors responded positively to the performance. The premium cinema technology company has continued to benefit from
More
Bonheur by Matt Abé has earned serious critical acclaim, winning two Michelin stars just eight months after opening, a vanishingly rare achievement in the culinary world. The restaurant is the solo venture
More
Roche is defending its ambitious long-term revenue forecasts for eye drug Vabysmo after the treatment fell short of analyst expectations for another quarter. Second-quarter sales of Vabysmo came in at approximately 1.04
More